BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15459213)

  • 1. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
    Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
    J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
    Gururangan S; Petros WP; Poussaint TY; Hancock ML; Phillips PC; Friedman HS; Bomgaars L; Blaney SM; Kun LE; Boyett JM
    Clin Cancer Res; 2006 Mar; 12(5):1540-6. PubMed ID: 16533779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
    Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
    Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
    Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.
    Jaeckle KA; Phuphanich S; Bent MJ; Aiken R; Batchelor T; Campbell T; Fulton D; Gilbert M; Heros D; Rogers L; O'Day SJ; Akerley W; Allen J; Baidas S; Gertler SZ; Greenberg HS; LaFollette S; Lesser G; Mason W; Recht L; Wong E; Chamberlain MC; Cohn A; Glantz MJ; Gutheil JC; Maria B; Moots P; New P; Russell C; Shapiro W; Swinnen L; Howell SB
    Br J Cancer; 2001 Jan; 84(2):157-63. PubMed ID: 11161370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
    Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
    Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
    Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
    Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option.
    Mastronuzzi A; Del Bufalo F; Iacono A; Secco DE; Serra A; Colafati GS; DE Ioris MA; Corsetti T
    Anticancer Res; 2013 Aug; 33(8):3515-8. PubMed ID: 23898128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
    Glantz MJ; Jaeckle KA; Chamberlain MC; Phuphanich S; Recht L; Swinnen LJ; Maria B; LaFollette S; Schumann GB; Cole BF; Howell SB
    Clin Cancer Res; 1999 Nov; 5(11):3394-402. PubMed ID: 10589750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
    Phuphanich S; Maria B; Braeckman R; Chamberlain M
    J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
    Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
    Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine.
    Prescrire Int; 2006 Feb; 15(81):11-2. PubMed ID: 16548098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis.
    Blaney SM; Heideman R; Berg S; Adamson P; Gillespie A; Geyer JR; Packer R; Matthay K; Jaeckle K; Cole D; Kuttesch N; Poplack DG; Balis FM
    J Clin Oncol; 2003 Jan; 21(1):143-7. PubMed ID: 12506183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia.
    Duarte RF; Arnan M; Sánchez-Ortega I; de Llano MP; Abellán PF
    Leuk Res; 2011 Jul; 35(7):e128-30. PubMed ID: 21501870
    [No Abstract]   [Full Text] [Related]  

  • 15. [Phase I study of intrathecal chemotherapy with NS-101 for leptomeningeal carcinomatosis in Japan].
    Nakagawa H; Tamura M; Fukushima Y; Majima S; Yamada K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1799-805. PubMed ID: 18030013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
    Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
    Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.
    Jaeckle KA; Batchelor T; O'Day SJ; Phuphanich S; New P; Lesser G; Cohn A; Gilbert M; Aiken R; Heros D; Rogers L; Wong E; Fulton D; Gutheil JC; Baidas S; Kennedy JM; Mason W; Moots P; Russell C; Swinnen LJ; Howell SB
    J Neurooncol; 2002 May; 57(3):231-9. PubMed ID: 12125986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
    Blaney SM; Balis FM; Berg S; Arndt CA; Heideman R; Geyer JR; Packer R; Adamson PC; Jaeckle K; Klenke R; Aikin A; Murphy R; McCully C; Poplack DG
    J Clin Oncol; 2005 Mar; 23(7):1555-63. PubMed ID: 15735131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
    Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
    J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2012 Aug; 109(1):143-8. PubMed ID: 22539243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.